The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
From nonpeptide toward noncarbon protease inhibitors: Metallacarboranes as specific and potent inhibitors of HIV protease
Open accessAbstract
HIV protease (PR) represents a prime target for rational drug design, and protease inhibitors (PI) are powerful antiviral drugs. Most of the current PIs are pseudopeptide compounds with limited bioavailability and stability, and their use is compromised by high costs, side effects, and development of resistant strains. In our search for novel PI structures, we have identified a group of inorganic compounds, icosahedral metallacarboranes, as candidates for a novel class of nonpeptidic PIs. Here, we report the potent, specific, and selective competitive inhibition of HIV PR by substituted metallacarboranes. The most active compound, sodium hydrogen butylimino bis-8,8-[5-(3-oxa-pentoxy)-3-cobalt bis(1,2-dicarbollide)]di-ate, exhibited a K i value of 2.2 nM and a submicromolar EC 50 in antiviral tests, showed no toxicity in tissue culture, weakly inhibited human cathepsin D and pepsin, and was inactive against trypsin, papain, and amylase. The structure of the parent cobalt bis(1,2-dicarbollide) in complex with HIV PR was determined at 2.15 Å resolution by protein crystallography and represents the first carborane-protein complex structure determined. It shows the following mode of PR inhibition: two molecules of the parent compound bind to the hydrophobic pockets in the flap-proximal region of the S3 and S3′ subsites of PR. We suggest, therefore, that these compounds block flap closure in addition to filling the corresponding binding pockets as conventional PIs. This type of binding and inhibition, chemical and biological stability, low toxicity, and the possibility to introduce various modifications make boron clusters attractive pharmacophores for potent and specific enzyme inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Self-citationFree R value: a novel statistical quantity for assessing the accuracy of crystal structures
Brünger, A. T. (1992) · Nature · doi:10.1038/355472a0 · Cited by 3,873
Principles of protein-protein interactions
Jones, S., & Thornton, J. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.13 · Cited by 2,684
HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy
Coffin, J. M. (1995) · Science · doi:10.1126/science.7824947 · Cited by 1,981
Active human immunodeficiency virus protease is required for viral infectivity
Kohl, N. E., Emini, E. A., Schleif, W. A., Davis, L. J., Heimbach, J. C., Dixon, R. A., Scolnick, E. M., & Sigal, I. S. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.13.4686 · Cited by 1,307
The Chemistry of Neutron Capture Therapy
Soloway, A. H., Tjarks, W., Barnum, B. A., Rong, F.-G., Barth, R. F., Codogni, I. M., & Wilson, J. G. (1998) · Chemical Reviews · doi:10.1021/cr941195u · Cited by 1,143
Friedman, S. H., DeCamp, D. L., Sijbesma, R. P., Srdanov, G., Wudl, F., & Kenyon, G. L. (1993) · Journal of the American Chemical Society · doi:10.1021/ja00068a005 · Cited by 954
Fullerene derivatives: an attractive tool for biological applications
Bosi, S., Da Ros, T., Spalluto, G., & Prato, M. (2003) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2003.09.005 · Cited by 834
Clavel, F., & Hance, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejm2ra025195 · Cited by 800
[17] The kinetics of reversible tight-binding inhibition
Williams, J. W., & Morrison, J. F. (1979) · Methods in Enzymology · doi:10.1016/0076-6879(79)63019-7 · Cited by 693
Applications of Radiolabeled Boron Clusters to the Diagnosis and Treatment of Cancer
Hawthorne, M. F., & Maderna, A. (1999) · Chemical Reviews · doi:10.1021/cr980442h · Cited by 559
Discovery and Selection of TMC114, a Next Generation HIV-1 Protease Inhibitor
Surleraux, D. L. N. G., Tahri, A., Verschueren, W. G., Pille, G. M. E., de Kock, H. A., Jonckers, T. H. M., Peeters, A., De Meyer, S., Azijn, H., Pauwels, R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049560p · Cited by 254
Recent advances in the chemistry of carborane metal complexes incorporating d- and f-block elements
Saxena, A. K., & Hosmane, N. S. (1993) · Chemical Reviews · doi:10.1021/cr00019a011 · Cited by 231
The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU
SPINELLI, S., LIU, Q., ALZARI, P., HIREL, P., & POLJAK, R. (1991) · Biochimie · doi:10.1016/0300-9084(91)90169-2 · Cited by 187
Mareš, M., MELOUN, B., Pavlík, M., Kostka, V., & Baudyš, M. (1989) · FEBS Letters · doi:10.1016/0014-5793(89)81435-8 · Cited by 142
Die Rolle der Chemie in der Entwicklung einer Krebstherapie durch die Bor‐Neutroneneinfangreaktion
Hawthorne, M. F. (1993) · Angewandte Chemie · doi:10.1002/ange.19931050705 · Cited by 132
Mildner, A. M., Rothrock, D. J., Leone, J. W., Bannow, C. A., Lull, J. M., Reardon, I. M., Sarcich, J. L., Howe, W. J., & Tomich, C.-S. C. (1994) · Biochemistry · doi:10.1021/bi00198a005 · Cited by 132
Domain Flexibility in Retroviral Proteases: Structural Implications for Drug Resistant Mutations,
Rose, R. B., Craik, C. S., & Stroud, R. M. (1998) · Biochemistry · doi:10.1021/bi9716074 · Cited by 113
Design of HIV-1 Protease Inhibitors Active on Multidrug-Resistant Virus
Surleraux, D. L. N. G., de Kock, H. A., Verschueren, W. G., Pille, G. M. E., Maes, L. J. R. M., Peeters, A., Vendeville, S., Meyer, S. D., Azijn, H., Pauwels, R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049454n · Cited by 73
Specific inhibition of HIV-1 protease by boronated porphyrins
DeCamp, D. L., Babé, L. M., Salto, R., Lucich, J. L., Koo, M., Kahl, S. B., & Craik, C. S. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00096a020 · Cited by 54
A new class of androgen receptor antagonists bearing carborane in place of a steroidal skeleton
Fujii, S., Hashimoto, Y., Suzuki, T., Ohta, S., & Endo, Y. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.09.091 · Cited by 53
Střı́šovský, K., Smrž, D., Fehrmann, F., Kräusslich, H., & Konvalinka, J. (2002) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2001.2728 · Cited by 11
Self-citation
Cited by
Boron Containing Compounds as Protease Inhibitors
Smoum, R., Rubinstein, A., Dembitsky, V. M., & Srebnik, M. (2012) · Chemical Reviews · doi:10.1021/cr608202m · Cited by 450
Grams, R. J., Santos, W. L., Scorei, I. R., Abad-García, A., Rosenblum, C. A., Bita, A., Cerecetto, H., Viñas, C., & Soriano-Ursúa, M. A. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00663 · Cited by 377
Challenges and Opportunities for the Application of Boron Clusters in Drug Design
Leśnikowski, Z. J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01932 · Cited by 348
Retroviral proteases and their roles in virion maturation
Konvalinka, J., Kräusslich, H.-G., & Müller, B. (2015) · Virology · doi:10.1016/j.virol.2015.03.021 · Cited by 148
Self-citationFoamy virus nuclear RNA export is distinct from that of other retroviruses
Bodem, J., Schied, T., Gabriel, R., Rammling, M., & Rethwilm, A. (2011) · Journal of Virology · doi:10.1128/jvi.01518-10 · Cited by 44
Self-citation
Metadata
- Authors
- Cígler, P., Kožíšek, M., Řezáčová, P., Brynda, J., Otwinowski, Z., Pokorná, J., Plešek, J., Grüner, B., Dolečková-Marešová, L., Máša, M., Sedláček, J., Bodem, J., Kräusslich, H.-G., Král, V., & Konvalinka, J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-10-14
- Volume
- 102
- Issue
- 43
- Pages
- 15394-15399
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2082332887
- Cited by
- 310
- References
- 22
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.